A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. (17th February 2022)

• Record Type: Journal Article
• Authors: Fargnoli, M. C.; Esposito, M.; Ferrucci, S.; Girolomoni, G.; Offidani, A.; Patrizi, A.; Peris, K.; Costanzo, A.; Malara, G.; Pellacani, G.; Romanelli, M.; Amerio, P.; Cristaudo, A.; Flori, M. L.; Motolese, A.; Betto, P.; Patruno, C.; Pigatto, P.; Peccianti, C.; Stinco, G.; Zalaudek, I.; Bianchi, L.; Boccaletti, V.; Cannavo, S. P.; Cusano, F.; Lembo, S.; Mozzillo, R.; Gallo, R.; Potenza, C.; Rongioletti, F.; Tiberio, R.; Grieco, T.; Micali, G.; Persechino, S.; Pettinato, M.; Pucci, S.; Stingeni, L.; Caruso, C.; Argenziano, G.;
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 2(2022)
• Page Start: 1146
• Page End: 1149
• Publication Date: 2022-02-17
• Subjects: Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2020.1773379
• Languages: English
• ISSNs: 0954-6634